PerioChip®

A biodegradable periodontal chip releasing 2.5mg Chlorhexidine Gluconate over a period of 10 days

Novel OTC formulation

Novel Formulation of a well-known US OTC Brand

Omeprazole DR Tablets

Proprietary Delayed Release Tablet Formulation of Omeprazole OTC

Complex Injectable
(Co-development)

Complex injectable product equivalent to a well-known brand in the oncology field; Co-developed with CSPC Pharma

ViePax® XR
(Venlafaxine XR tablets)

Proprietary Extended Release Tablet formulation bioequivalent to capsule Effexor XR capsules

Company Profile

Dexcel Pharma is Israel’s largest private pharmaceutical

company. Founded in 1968, we develop, manufacture

and market value-added branded and generic

pharmaceuticals. With a diverse product portfolio that

spans more than 85 branded and generic products in

over 175 dosage forms, our products are sold in the US,

the UK and Germany, via subsidiaries and through a

trusted network of partners in more than 30 countries worldwide.

 

Track Record of Market innovation and Success

History of successful development and commercialization of novel drug formulations utilizing Dexcel’s proprietary drug delivery technologies. Dexcel’s Omeprazole Delayed-Release Tablet – a Proton Pump Inhibitor – is the bestselling Over-The-Counter product in the US heartburn market category.

 

 

Sophisticated R&D

Dexcel’s R&D approach applies creative thinking across multiple dimensions to bring innovation to address patient unmet needs. Dexcel’s philosophy calls for imagination in drug formulation, sophisticated regulatory strategy, and careful product selection.

 

State-of-the-art Manufacturing

Fully automated manufacturing facilities for oral solid dose forms are located in the central Israel city of Or Akiva, alongside corporate headquarters and R&D. Additional research and manufacturing facilities are located in Yokneam and Jerusalem.